Teva Pharmaceutical Industries’ (TEVA) Overweight Rating Reiterated at Piper Sandler

Piper Sandler reiterated their overweight rating on shares of Teva Pharmaceutical Industries (NYSE:TEVA) in a research note released on Wednesday,Benzinga reports. The brokerage currently has a $41.00 price objective on the stock, up from their prior price objective of $40.00.

Other equities research analysts also recently issued reports about the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, January 21st. Jefferies Financial Group lifted their target price on shares of Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday, January 6th. Truist Financial boosted their target price on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a “buy” rating in a research note on Wednesday, February 18th. Wall Street Zen raised Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 31st. Finally, Scotiabank increased their price target on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company a “sector outperform” rating in a research report on Thursday, January 29th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Teva Pharmaceutical Industries presently has an average rating of “Moderate Buy” and an average price target of $37.67.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE:TEVA opened at $31.06 on Wednesday. The company has a current ratio of 1.04, a quick ratio of 0.80 and a debt-to-equity ratio of 1.89. The stock has a market cap of $35.71 billion, a PE ratio of 25.88, a price-to-earnings-growth ratio of 10.63 and a beta of 0.72. The stock’s fifty day simple moving average is $33.01 and its two-hundred day simple moving average is $26.20. Teva Pharmaceutical Industries has a 1-year low of $12.47 and a 1-year high of $37.35.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Wednesday, January 28th. The company reported $0.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.31. The firm had revenue of $4.71 billion during the quarter, compared to analyst estimates of $4.36 billion. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 46.28%. The business’s revenue was up 11.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.71 EPS. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. As a group, analysts forecast that Teva Pharmaceutical Industries will post 2.5 EPS for the current fiscal year.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, CEO Richard D. Francis sold 442,935 shares of Teva Pharmaceutical Industries stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $32.36, for a total value of $14,333,376.60. Following the sale, the chief executive officer owned 642,099 shares of the company’s stock, valued at approximately $20,778,323.64. The trade was a 40.82% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Roberto Mignone sold 77,400 shares of the business’s stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $30.24, for a total transaction of $2,340,576.00. Following the completion of the transaction, the director owned 367,600 shares in the company, valued at approximately $11,116,224. The trade was a 17.39% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 1,210,805 shares of company stock valued at $38,221,390 in the last three months. 0.49% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Several institutional investors have recently bought and sold shares of TEVA. AQR Capital Management LLC grew its holdings in Teva Pharmaceutical Industries by 24.6% during the first quarter. AQR Capital Management LLC now owns 23,955 shares of the company’s stock valued at $368,000 after purchasing an additional 4,732 shares during the period. Focus Partners Wealth raised its stake in shares of Teva Pharmaceutical Industries by 4.5% in the first quarter. Focus Partners Wealth now owns 40,074 shares of the company’s stock valued at $616,000 after buying an additional 1,739 shares during the period. Assetmark Inc. raised its stake in shares of Teva Pharmaceutical Industries by 137.2% in the second quarter. Assetmark Inc. now owns 20,075 shares of the company’s stock valued at $336,000 after buying an additional 11,613 shares during the period. Bank of Montreal Can lifted its position in shares of Teva Pharmaceutical Industries by 15.9% during the 2nd quarter. Bank of Montreal Can now owns 475,937 shares of the company’s stock valued at $7,977,000 after buying an additional 65,191 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its position in shares of Teva Pharmaceutical Industries by 4.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,682,837 shares of the company’s stock valued at $28,204,000 after buying an additional 73,141 shares during the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.